Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer

Overview of attention for article published in Drug Design, Development and Therapy, October 2015

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 34 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 34 followers.

Crizotinib for ALK-positive NSCLC in previously treated patients http://t.co/n5xpUHDvoz

Reply Repost Favourite